Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients
To prove that the efficacy and safety of 'Green Cross CELL\* Immuncell-LC group' is superior to 'non-treatment group(Control group)' in patient undergone curative resection(PEIT, RFA or operation) for hepatocellular carcinoma in Korea
Hepatocellular Carcinoma
BIOLOGICAL: Immuncell-LC
Recurrence Free Survival(RFS), RFS was measured from the date of randomization to the first recurrence or to death from any cause., Every 3months from the baseline for 24 months and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Recurrence Free Survival(RFS) Rate, RFS rate was measured from the date of randomization to the first recurrence or to death from any cause., Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)
Overall Survival(OS), Overall survival was measured from the date of randomization until death from any cause., Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Cancer-specific Survivals, Cancer-specific survival was measured from the date of randomization until death resulting from HCC., Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Overall Survival(OS) Rate, Overall survival rate was measured from the date of randomization until death from any cause., Every 3months from the baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)|Cancer-specific Survival Rate, Cancer-specific survival rate was measured from the date of randomization until death resulting from HCC., Every 3 months from baseline for 24 months, and then every 3-6 months until the data cut-off date, up to LSLV(Last Subject Last Visit)
Multicenter, randomized, open-labeled phase 3 clinical trial.